Concepedia

Publication | Open Access

Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial

DOIFull Paper Access

37

Citations

15

References

2021

Year

Richard Cowan, Julia Scarisbrick, Pier Luigi Zinzani, Jan P. Nicolay, Lubomir Sokol, Lauren Pinter‐Brown, Pietro Quaglino, Lars Iversen, Reinhard Dummer, Amy Musiek,
Journal of the European Academy of Dermatology and Venereology

Abstract

This post hoc analysis indicates greater clinical benefit with mogamulizumab vs. vorinostat in patients with MF and SS classified as having B1 and B2 blood involvement.

References

YearCitations

Page 1